Nature Search

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

SECOMBIT was a clinical trial testing different sequences of immunotherapy (ipilimumab plus nivolumab) and targeted therapy (encorafenib plus binimetinib) for untreated BRAF-mutated metastatic melanoma. Here the authors report 4-year survival outcomes, confirming long-term benefit with first-line immunotherapy, and preliminary biomarkers evaluation.

Paolo A. Ascierto
Milena Casula
Giuseppe Palmieri
ResearchOpen Access02 Jan 2024
Nature Communications

Volume: 15, P: 1-12
Nitric Oxide Produced by the Enterocyte Is Involved in the Cellular Regulation of Ion Transport

Roberto Berni Canani
Pia Cirillo
Alfredo Guarino
Research01 Jul 2003
Pediatric Research

Volume: 54, P: 64-68
Pharmacological folding chaperones act as allosteric ligands of Frizzled4

Several GPCRs have ligands that act as pharmacological chaperones that rescue function of mutated receptors. This formed the basis of a screening strategy to identify new ligands for Frizzled4 that act allosterically at an effector domain to inhibit β-catenin signaling.

Serena F Generoso
Mariateresa Giustiniano
Mariano Stornaiuolo
Research09 Mar 2015
Nature Chemical Biology

Volume: 11, P: 280-286
Impairment of T cell development and acute inflammatory response in HIV-1 Tat transgenic mice

Giuseppe Fiume
Annarita Scialdone
Ileana Quinto
ResearchOpen Access07 Sept 2015
Scientific Reports

Volume: 5, P: 1-14
FABP5 is a key player in metabolic modulation and NF-κB dependent inflammation driving pleural mesothelioma

Pleural mesothelioma (PM) exhibits altered lipid metabolism and NFκB dysregulation, driven by FABP5, promoting tumor growth and inflammation. Silencing FABP5 alters cell dynamics, suggesting it as a potential therapeutic target in PM.

Eleonora Vecchio
Raffaella Gallo
Giuseppe Fiume
ResearchOpen Access27 Feb 2025
Communications Biology

Volume: 8, P: 1-13
The expression of inhibitor of bruton’s tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis

Francesco Albano
Federico Chiurazzi
Ileana Quinto
ResearchOpen Access09 Jan 2018
Cell Death & Disease

Volume: 9, P: 1-10

Quick links

Search

Filter By:

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

Nitric Oxide Produced by the Enterocyte Is Involved in the Cellular Regulation of Ion Transport

Pharmacological folding chaperones act as allosteric ligands of Frizzled4

Impairment of T cell development and acute inflammatory response in HIV-1 Tat transgenic mice

FABP5 is a key player in metabolic modulation and NF-κB dependent inflammation driving pleural mesothelioma

The expression of inhibitor of bruton’s tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis

Search

Quick links